Lotion and tablet for dry, sensitive skin with itching or hives
Part of Immune system & allergy, Skin clinical trials.
This study tests a lotion and tablet combination for people with dry or sensitive skin that is prone to mild to moderate itching or hives. Researchers want to see if the products are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have dry or sensitive skin that itches or has hives (mild to moderate).
- Your skin at the application site is free of cuts, tattoos, scars, sunburn, or excessive hair.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use birth control if needed.
- You have not used other medicated skin products or joined a similar study in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of cosmetic products for people with dry, very dry, or itchy skin. The goal is to see if these products help soothe your skin and reduce itching.
This trial tests a new skincare product for dry or sensitive skin to see if it is safe and works well. Healthy adults with dry or sensitive skin who are not using other medicated skin products may join.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This trial tests a mobile app designed to help reduce itching and related symptoms for people with psoriasis, eczema, or chronic hives. If you have moderate to severe itch and can use an English-language app, this study might be for you.
This trial tests a gel containing hyaluronic acid (a natural skin moisturizer) to quickly relieve moderate-to-severe itching from conditions like eczema, bug bites, or hives. The study measures how well it works and how safe it is.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
Hear when a new Dry Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.